| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RAMP1 |
| Uniprot No | O60894 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-117aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSCQEANYG ALLRELCLTQ FQVDMEAVGE TLWCDWGRTI RSYRELADCT WHMAEKLGCF WPNAEVDRFF LAVHGRYFRS CPISGRAVRD PPGS |
| 预测分子量 | 13 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RAMP1重组蛋白研究的模拟参考文献示例(文献为虚构，仅供格式参考)：
1. **文献名称**: "Recombinant Expression and Functional Characterization of RAMP1 in Complex with the Calcitonin Receptor-like Receptor"
**作者**: Smith A, et al.
**摘要**: 研究通过哺乳动物细胞系统重组表达RAMP1与CLR蛋白复合物，证实其与CGRP结合的功能，并分析其在细胞信号转导中的作用。
2. **文献名称**: "Structural Insights into RAMP1-Mediated Modulation of CGRP Receptor Activation"
**作者**: Tanaka K, et al.
**摘要**: 利用冷冻电镜技术解析RAMP1与受体复合物的三维结构，揭示RAMP1对配体结合特异性和受体激活的关键调控机制。
3. **文献名称**: "Optimization of RAMP1 Recombinant Protein Production in E. coli for Drug Screening Applications"
**作者**: Lee J, et al.
**摘要**: 报道在大肠杆菌中高效表达可溶性RAMP1重组蛋白的优化策略，验证其与拮抗剂结合活性，为抗偏头痛药物开发提供工具。
4. **文献名称**: "RAMP1 Knockout and Recombinant Rescue Models Reveal Its Role in Neuropathic Pain"
**作者**: Chen R, et al.
**摘要**: 通过重组RAMP1蛋白回补实验，证明其在神经炎症模型中对疼痛信号通路的调节作用，提示其作为治疗靶点的潜力。
注：以上为模拟文献，实际研究需通过学术数据库(如PubMed)检索真实文献。
**Background of RAMP1 Recombinant Protein**
Receptor Activity-Modifying Protein 1 (RAMP1) is a member of the RAMP family, a group of single-pass transmembrane proteins that regulate the trafficking, ligand specificity, and signaling of G protein-coupled receptors (GPCRs). RAMP1 is best known for its interaction with the calcitonin receptor-like receptor (CLR), forming the heterodimeric calcitonin gene-related peptide (CGRP) receptor. This receptor plays a critical role in neurotransmission, vasodilation, and neurogenic inflammation, making it a key target in migraine pathophysiology.
RAMP1 stabilizes CLR at the cell membrane and determines its ligand selectivity. Without RAMP1. CLR functions as an adrenomedullin receptor; however, their co-expression enables selective binding of CGRP, a neuropeptide implicated in pain signaling. Dysregulation of the CGRP-RAMP1-CLR axis is linked to chronic migraines, prompting the development of anti-CGRP/RAMP1 therapeutics like monoclonal antibodies (e.g., erenumab) and small-molecule antagonists.
Recombinant RAMP1 protein is produced using biotechnological systems (e.g., mammalian, insect, or bacterial cells) to express purified, functional RAMP1 for research and drug discovery. Its applications include structural studies to elucidate receptor-ligand interactions, in vitro assays for screening CGRP pathway inhibitors, and antibody production. Recombinant RAMP1 also aids in exploring cross-species receptor variations and mechanisms underlying RAMP-mediated GPCR modulation.
As migraine therapies targeting CGRP signaling advance, RAMP1 remains a focus for understanding receptor biology and designing next-generation therapeutics. Its role in other conditions, such as cardiovascular diseases and inflammation, further underscores its biomedical relevance.
×
